title: Impact of gender on statin efficacy.
abstract: OBJECTIVE
  To determine the impact of statin therapy on the combined endpoint of cardiovascular events in women and men separately.
  
  
  METHODS
  A systematic literature search through May 2006 was conducted to identify randomized, controlled statin trials evaluating the gender specific incidence of cardiovascular events. Weighted averages were reported as relative risks (RRs) with 95% confidence intervals (CI) calculated via random-effects model.
  
  
  METHODS
  The primary outcome measured was a composite endpoint of all cardiovascular events. Secondary outcomes measured included death, myocardial infarction (MI), and stroke.
  
  
  RESULTS
  Fifteen trials were included in this meta-analysis. Cardiovascular events were reduced in men (RR 0.76 [95% CI 0.70, 0.81]) and women (RR 0.79 [95% CI 0.69, 0.90]). Reductions in mortality, MI, and stroke predominantly contributed to the reduction in cardiovascular events in men taking statins. Women did not have a reduction in mortality or stroke, suggesting that the reductions in cardiac events may have been predominantly due to reductions in need for revascularization and/or unstable angina.
  
  
  CONCLUSIONS
  Statins reduced the risk of cardiovascular events in men and women, but women on statins may not have reductions in mortality and stroke like their male counterparts.
authors.affiliation: University of Connecticut School of Pharmacy, Storrs, CT, USA.
authors.forename: Krista M
authors.initials: KM
authors.lastname: Dale
authors.forename: Craig I
authors.initials: CI
authors.lastname: Coleman
authors.forename: Sachin A
authors.initials: SA
authors.lastname: Shah
authors.forename: Aarti A
authors.initials: AA
authors.lastname: Patel
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Kluger
authors.forename: C Michael
authors.initials: CM
authors.lastname: White
mesh_terms: D017677:Age Distribution; D000368:Aged; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000517:prevention & control; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006949:Hyperlipidemias / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D017035:Pravastatin / Q000008:administration & dosage; D011336:Probability; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D019821:Simvastatin / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin; D017035:Pravastatin